Navigation Links
NightHawk Radiology Holdings, Inc. to Speak at the Cowen and Company 28th Annual Health Care Conference on March 18, 2008
Date:2/28/2008

COEUR D'ALENE, Idaho, Feb. 28 /PRNewswire-FirstCall/ -- NightHawk Radiology Holdings, Inc. (Nasdaq: NHWK), the leading provider of radiology solutions to radiology groups and hospitals throughout the United States, today announced that it will present at the Cowen and Company 28th Annual Health Care Conference on Tuesday, March 18, 2008, at 11:00 am EDT at the Boston Marriott Copley Place in Boston, MA. Dr. Paul Berger, Chairman and Chief Executive Officer, Andrea Clegg, Vice President of Finance and Jon Berger, Senior Vice President of Business Development & Strategy will share information about the company, its strategy and service offerings. A live and archived copy of the webcast will be available on the investor relations section of NightHawk's website at http://www.nighthawkrad.net.

About NightHawk

NightHawk Radiology (Nasdaq: NHWK), headquartered in Coeur d'Alene, Idaho, is leading the transformation of the practice of radiology by providing high-quality, cost-effective solutions to radiology groups and hospitals throughout the United States. NightHawk provides the most complete suite of solutions, including professional services, business services, and its advanced, proprietary clinical workflow technology, all designed to increase efficiencies and improve the quality of patient care and the lives of physicians who provide it. NightHawk's team of U.S. board-certified, state-licensed, and hospital-privileged physicians located in the United S
'/>"/>

SOURCE NightHawk Radiology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. NightHawk Radiology Holdings, Inc. Announces Date for Third Quarter Earnings Conference Call
2. NightHawk Radiology Holdings, Inc. Releases Record Third Quarter 2007 Results
3. NightHawk Radiology Holdings, Inc. to Speak at Annual Piper Jaffray Healthcare Conference on November 28, 2007
4. NightHawk Radiology: One Source, One Solution
5. NightHawk Radiology Holdings, Inc. to Speak at Annual JPMorgan Healthcare Conference on January 10, 2008
6. NightHawk Radiology Holdings, Inc. Announces Preliminary 2007 Results
7. NightHawk Radiology Holdings, Inc. Announces Date for Fourth Quarter and Full-Year 2007 Earnings Conference Call
8. NightHawk Radiology exclusive radiology provider for high-risk plaque research initiative
9. NightHawk Radiology Holdings, Inc. Announces Time Change for Fourth Quarter and Full-Year 2007 Earnings Conference Call
10. NightHawk Radiology Holdings, Inc. Announces Fourth Quarter and Full-Year 2007 Results; Updates 2008 Guidance
11. AIUM CEO named among most influential in radiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2008)...e/ -- As the global community observes,the destruc...yclone of all,time and the associated mounting fru... victims, the Alumni Myanmar Institutes of Medicin...importantly, successful-in initiating,medical care...000 people,are assumed dead. AMIMA has funded the ...
(Date:5/11/2008)... -- The winners of today,s Susan G.,Komen Pittsbur...ace Overall Winners Male: Pat McGuire, Charl...bein, Pittsburgh, Pa., 19:19, 2nd Place Overall W...: Anna Beck, Washington, Pa., 19:22, 3rd Place O..., Pa., 16:13 Female: Jessica Winter, Pittsbu...
(Date:5/11/2008)...nd for Unveiling of the New Name of the ...HICAGO, May 11 /PRNewswire/ -- Thousands of people...ntry were present for the unveiling of the,new nam...t cancer,organization, This year, Y-ME National B...h anniversary. In celebration of this landmark, Y-...
(Date:5/10/2008)...orts to Gain Clearance for Airlift of ... May 10 /PRNewswire-USNewswire/ -- An AmeriCares,e...today to assess the,crisis situation and continue ...ion,s airlift of 15 tons of essential medicines an...king closely with the World Health Organization to...
Breaking Medicine News(10 mins):Health News:Alumni Myanmar Institutes of Medicine Association (AMIMA) Races Time to Help Cyclone Victims 2Health News:16th Annual Komen Pittsburgh Race for the Cure(R) Winners Announced 2Health News:Y-ME Makes Historic Announcement on Mother's Day 2Health News:Y-ME Makes Historic Announcement on Mother's Day 3Health News:AmeriCares Relief Worker Arrives in Myanmar 2
... government announced plans on Thursday to ban all... of the clitoris which just days ago cost the lif... which affects both Muslim and Christian women in ...he pharaohs, was banned in 1997 but doctors were a...
...alth Organization (WHO) has said that the risk of ...tely doubles after travel of four hours or more. ...the WHO, however, says that the absolute risk of d...d and immobile for more than four hours remains re...
...surgical students stick themselves with needles an... resulting injuries could be infectious and very ...a new study by reported Martin Makary, M.D., a sur...s Hospital, and colleagues, in the June 28 issue o...
...ls, a leading healthcare provider in Andhra Prades...llion during the next one year to set up new stat...are brand, which has just completed 10 years, plan... in Madhya Pradesh, Maharashtra, Chhattisgarh, Guj...
Other Medicine News:Health News:Egypt Outlaws All Female Circumcision 2Health News:Thrombosis Risk in Travel Lasting Over Four Hours is Higher: WHO 2Health News:Surgical Students Fail to Report Needle Stick Injuries 2Health News:Surgical Students Fail to Report Needle Stick Injuries 3
(Date:5/8/2008)...Call/ -- DATATRAK International, Inc.,(Nasdaq: DA... global,eClinical solutions for the clinical trial...or the first quarter of 2008., For the three mont...mately 41% to $2,088,000 and the Company reported ...n both a basic and diluted basis. These,results co...
(Date:5/8/2008)...tial of asenapine in the treatment of ...GTON, May 8 /- Schering-Plo... an overview of asenapine clinical trials,from the... Meeting of the,American Psychiatric Association i..., involving patients with bipolar I disorder and s...
(Date:5/8/2008)...e-FirstCall/ -- VION PHARMACEUTICALS,INC. (Nasdaq...ator-sponsored,Phase I/II clinical trial of its le...combination with cytarabine in elderly patients wi... (AML) and high-risk,myelodysplastic syndromes (MD...on of Ellen K. Ritchie, M.D. at The Weill-Cornell ...
(Date:5/8/2008)...e-FirstCall/ -- AstraZeneca (NYSE:,AZN) today anno...plication,(sNDA) to the U.S. Food and Drug Adminis...rate) Extended-Release Tablets to seek approval fo...AD), including maintenance of,antianxiety effect. ...an,atypical antipsychotic medicine in GAD. The sub...
Breaking Medicine Technology:DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 1Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 2Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 3Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 4More Black Children Dying From Diabetes 6447 1More Black Children Dying From Diabetes 6447 2More Black Children Dying From Diabetes 6447 3Carnegie Mellon neuroscientist proposes new theory of brain flexibility 6442 1Carnegie Mellon neuroscientist proposes new theory of brain flexibility 6442 2Carnegie Mellon neuroscientist proposes new theory of brain flexibility 6442 3TriWest Executive Advisory Board Marks Its Fifth Year 6438 1TriWest Executive Advisory Board Marks Its Fifth Year 6438 2TriWest Executive Advisory Board Marks Its Fifth Year 6438 3
...O, Calif., May 02, 2007 /PRNewswire/ -- Ceregene, ...Phase 1 trial of,CERE-110, a gene therapy product ...the treatment of Alzheimer,s disease. After one,ye...who received,CERE-110 in the trial indicate that a...erated, and an interim analysis suggested that,the...
....C.--(BUSINESS WIRE)--May 4, 2007 - Argos Therapeu...he immunosuppressive,properties of soluble CD83 at...eld in San Francisco, May 5-9. The presentations,w...e University of,Western Ontario., "These data sugg...ival in transplantation, and that it can also act,...
Other Medicine Technology:Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 2Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 3Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 4Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: